



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup>:</b> <b>C12N 7/01, A61K 39/40, C07K 16/12 //</b> <b>19/00</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 97/29185</b>  <b>(43) International Publication Date:</b> 14 August 1997 (14.08.97)
<b>(21) International Application Number:</b> PCT/SE97/00172 <b>(22) International Filing Date:</b> 5 February 1997 (05.02.97)  <b>(30) Priority Data:</b> 9600434-6      6 February 1996 (06.02.96)      SE  <b>(71)(72) Applicant and Inventor:</b> MÁRDH, Sven [SE/SE]; Sjöliden 13, S-590 77 Vreta Kloster (SE).  <b>(74) Agent:</b> GÖTEBORGS PATENTBYRÅ AB; P.O. Box 5005, S-402 21 Göteborg (SE).		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent: (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  Published <i>With international search report.</i>
<b>(54) Title:</b> RECOMBINANT PHAGES  <b>(57) Abstract</b> <p>The present invention relates to bacteriophages for use in the treatment or prophylaxis of bacterial infections, especially mucosal bacterial infections such as <i>Helicobacter pylori</i> infections. In particular, it relates to modified filamentous bacteriophages, e.g. M13 phages, for such use, which bacteriophages present at its surface a recombinant protein comprising: (i) a first component derived from a bacteriophage surface protein; and (ii) a second component comprising variable region sequences of an antibody to provide a bacterial antigen binding site, said second component rendering said bacteriophage capable of binding to and thereby inhibiting growth of bacterial cells involved in the etiology of said infection.</p>		